Markers of Inflammation Are Generally Elevated in Schizophrenia-Spectrum Disorders
Investigators searched publication databases for studies reporting biomarkers for inflammation in schizophrenia-spectrum disorders.
Investigators searched publication databases for studies reporting biomarkers for inflammation in schizophrenia-spectrum disorders.
In this study, the changes in Scale for Assessment for Positive Symptoms, Scale for Assessment of Negative Symptoms, and Global Assessment of Functioning scale outcomes over 20 years were evaluated.
Investigators sought to evaluate the association of comorbid PD and SUD with the probability of hospitalization among patients with COVID-19 in the emergency department.
In this analysis, the children who had 1 or both parents with schizophrenia or bipolar disorder were matched with children without familial high risk for psychosis.
Investigators sourced data for this study from the United Kingdom Biobank, 23andMe, and the Psychiatric Genomics Consortium dataset.
The approval was based on data from adequate and well-controlled studies with risperidone long-acting injection (intramuscular).
The NDA is supported by data from a phase 1/2 trial that compared the investigational aripiprazole 2-month, long-acting injectable to aripiprazole 1-month depot.
The phase 3 EMERGENT-2 trial included 252 patients with schizophrenia who were experiencing symptoms of psychosis.
To assess the impact of multimodal speech-gesture training on patients’ communication abilities, investigators conducted a randomized waiting list-controlled pilot trial at a university in Marburg, Germany.
The researchers conducted secondary analysis of a multi-site CET trial using 86 individuals recently diagnosed with a schizophrenia spectrum disorder.